Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2234-2242

  Symowicz, Jaime ^a   Adley, Brian P ^a   Woo, Michelle M M ^b   Auersperg, Nely ^b   Hudson, Laurie G ^c   Stack, M Sharon ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; RAS PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOMA CELL; CELL IMMORTALIZATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEDIATOR; METASTASIS; OVARY CARCINOMA; OVARY CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL MOVEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME INDUCTION; ENZYME PRECURSORS; FEMALE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; OVARIAN NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, LYSOSPHINGOLIPID; TRANS-ACTIVATION (GENETICS);

EID: 16844378151     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008.5472.CAN-04-2781     Document Type: Article

References (75)

1. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: the national ovarian cancer early detection program (NOCEDP). Stack MS, Fishman DA, editors. Cancer Treatment and Research: Ovarian Cancer. Boston: Kluwer Academic Publishers; 2001. p. 3-28.
2. Fang X, Gaudette D, Furui T, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 2000;905:188-208
3. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223-32.
4. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437-42.
5. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002;1582:257-64.
6. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-72.
7. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs. nonmalignant ascitic fluids. Anal Biochem 2001;290:302-13.
8. Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Stack MS, Fishman DA, editors. Cancer Treatment and Research: Ovarian Cancer. Boston: Kluwer Academic Publishers; 2001. p. 259-84.
9. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001;61:3194-9.
10. Reiser CO, Lanz T, Hoffman F, Hofer G, Rupprecht HD, Goppelt-Struebe M. Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response gene prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38 and for Rho proteins. Biochem J 1998;330:1107-14.
11. Moolenar WH, Kruijer W, Tilly BC, Verlaan I, Bierman AJ, de Laat SW. Growth factor-like action of phosphatidic acid. Nature 1986;323:171-3.
12. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-8.
13. Schwartz BM, Hong G, Morrison BH, et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001;81:291-300.
14. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
15. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-86.
16. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
17. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000;49:367-92.
18. Dempke W, Rie C, Grothey A, Schmoll H-J. Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer Res Clin Oncol 2001;127:411-7.
19. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160:893-903.
20. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001;8:31-6.
21. Landen CN, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 2003;188:1174-6.
22. Li S, Miner K, Fannin R, Barrett JC, Davis BJ. Cyclooxygenase-1 and 2 in normal and malignant ovarian epithelium. Gynecol Oncol 2004;92:622-7.
23. Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001;358:1287-8.
24. Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001;16:1323-8.
25. Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91:197-208.
26. Tsafriri A. Ovulation as a tissue remodeling process. Proteolysis and cumulus expansion. Adv Exp Med Biol 1995;377:121-40.
27. Butler TA, Zhu C, Mueller RA, Fuller GC, Lemaire WJ, Woessner JF Jr. Inhibition of ovulation in the perfused rat ovary by the synthetic collagenase inhibitor SC44463. Biol Reprod 1991;44:1183-8.
28. Klimp AH, Hollema H, Kempinga C, van der Zee AGJ, de Vries EGE, Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001;61:7305-9.
29. Ali-Fehmi R, Che M, Khalifen I, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003;98:1423-9.
30. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-11.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970;227:680-5.
32. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem 1987;262:10035-8.
33. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
34. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 1997;94:657-62.
35. Vadlamudi R, Mandai M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14.
36. Laffargue M, Raynal P, Yart A, et al. An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid. J Biol Chem 1999;274:32835-41.
37. Gshwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth receptor signal transactivation. Cancer Res 2002;62:6329-36.
38. Kim SN, Park JC, Lee EB, Kim SS, Yoo YS. Characteristics of epidermal growth factor receptor function in lysophosphatidic acid signaling in PC12 cells. J Cell Biochem 2000;76:386-93.
39. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal Characteristics of G protein-transactivated EGF receptor. EMBO J 1997;16:7032-44.
40. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379,557-60.
41. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
42. Attiga FA, Fernandez PM, Manyak MJ, Patierno SR. Effect of the cyclooxygenase-2-selective inhibitor NS398 on the secretion of matrix metalloproteinases (MMP2 and MMP9) and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) from human prostate tumor cells. Proc Am Assoc Cancer Res 2000;41:131-2.
43. Pan M-R, Chuang L-Y, Hung W-C. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001;508:365-8.
44. Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999;5:3704-10.
45. Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62:6015-20.
46. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Charraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-74.
47. Eibl G, Bruemmer D, Okada Y, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003;306:88-897.
48. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial cell spreading, migration, and angiogenesis. Nat Med 2001;7:1041-7.
49. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin αVβ3-dependent endothelial adhesion, rac-activation, and spreading through camp/PKA-dependent signaling. J Biol Chem 2002;277:45838-46.
50. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002;85:305-10.
51. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1185-91.
52. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001;93:1375-84.
53. Brader KH, Wolf JK, Chakrabarty S, Price JE. Epidermal growth factor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Rep 1998;5:1269-74.
54. Alper O, DeSantis ML, Stromberg K, Hacker NF, Cho-Chung YS, Salomon DS. Antisense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell adhesion, and tumorigenicity in ovarian cancer cells. Int J Cancer 2000;88:566-74.
55. Sheng H, Shao J, DuBois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B. Cancer Res 2001;61:2670-5.
56. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase 2 levels in patients with gastric carcinoma. Cancer 2001;91:1876-81.
57. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
58. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001;20:1594-600.
59. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997;16:7032-44.
60. Wang S-C, Lien H-C, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-61.
61. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002;8:202-9.
62. 1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not COX-2-specific RNA interference. Oncogene 2003;22:8653-61.
63. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
64. Elder DJE, Halton DE, Crew TE, Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553-60.
65. Elder DJE, Halton DE, Playle LC, Paraskeva C. The MEK/ERK pathway mediates COX-2 selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002;99:323-7.
66. Molina M, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinoma and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
67. Mills GB. Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res 2002;8:7-10.
68. Akhmendkhanov AA, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and risk of epithelial cancer. Prev Med 2001;33:682-7.
69. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2001;11:1171-3.
70. Smith ER, Daly MB, Xu X-X. A mechanism for COX-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev 2004;13:144-5.
71. Munkarah AR, Genhai Z, Morris R, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003;88:429-33.
72. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2545-50.
73. Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003;125:716-29.
74. Roland IH, Yang W-L, Yang D-H, et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylatic oophorectomies. Cancer 2003;98:2607-23.
75. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt H, et al. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 2003;88:1445-52.